X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs DR. REDDYS LAB - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS DR. REDDYS LAB IPCA LABS/
DR. REDDYS LAB
 
P/E (TTM) x 42.2 29.9 141.1% View Chart
P/BV x 3.2 2.9 110.4% View Chart
Dividend Yield % 0.2 0.9 17.2%  

Financials

 IPCA LABS   DR. REDDYS LAB
EQUITY SHARE DATA
    IPCA LABS
Mar-17
DR. REDDYS LAB
Mar-17
IPCA LABS/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs6433,397 18.9%   
Low Rs5032,560 19.6%   
Sales per share (Unadj.) Rs254.4856.5 29.7%  
Earnings per share (Unadj.) Rs16.178.0 20.6%  
Cash flow per share (Unadj.) Rs29.8139.9 21.3%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %0.20.7 26.0%  
Book value per share (Unadj.) Rs194.6739.8 26.3%  
Shares outstanding (eoy) m126.20165.74 76.1%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x2.33.5 64.8%   
Avg P/E ratio x35.738.2 93.3%  
P/CF ratio (eoy) x19.221.3 90.4%  
Price / Book Value ratio x2.94.0 73.1%  
Dividend payout %6.225.7 24.3%   
Avg Mkt Cap Rs m72,300493,632 14.6%   
No. of employees `00013.322.7 58.7%   
Total wages/salary Rs m6,96031,068 22.4%   
Avg. sales/employee Rs Th2,413.56,259.0 38.6%   
Avg. wages/employee Rs Th523.21,369.8 38.2%   
Avg. net profit/employee Rs Th152.4569.7 26.8%   
INCOME DATA
Net Sales Rs m32,106141,961 22.6%  
Other income Rs m2261,715 13.2%   
Total revenues Rs m32,332143,676 22.5%   
Gross profit Rs m4,44824,722 18.0%  
Depreciation Rs m1,73010,266 16.8%   
Interest Rs m241634 38.0%   
Profit before tax Rs m2,70315,537 17.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6752,965 22.8%   
Profit after tax Rs m2,02812,921 15.7%  
Gross profit margin %13.917.4 79.5%  
Effective tax rate %25.019.1 130.9%   
Net profit margin %6.39.1 69.4%  
BALANCE SHEET DATA
Current assets Rs m17,34096,837 17.9%   
Current liabilities Rs m9,55984,199 11.4%   
Net working cap to sales %24.28.9 272.2%  
Current ratio x1.81.2 157.7%  
Inventory Days Days10073 136.7%  
Debtors Days Days5798 58.2%  
Net fixed assets Rs m20,779102,552 20.3%   
Share capital Rs m252829 30.4%   
"Free" reserves Rs m24,499121,792 20.1%   
Net worth Rs m24,553122,621 20.0%   
Long term debt Rs m3,5175,449 64.6%   
Total assets Rs m39,595218,165 18.1%  
Interest coverage x12.225.5 47.9%   
Debt to equity ratio x0.10 322.4%  
Sales to assets ratio x0.80.7 124.6%   
Return on assets %5.76.2 92.2%  
Return on equity %8.310.5 78.4%  
Return on capital %10.512.9 81.3%  
Exports to sales %48.654.6 89.1%   
Imports to sales %14.29.4 152.3%   
Exports (fob) Rs m15,61777,520 20.1%   
Imports (cif) Rs m4,57113,274 34.4%   
Fx inflow Rs m15,61781,670 19.1%   
Fx outflow Rs m5,82826,355 22.1%   
Net fx Rs m9,79055,315 17.7%   
CASH FLOW
From Operations Rs m2,76421,444 12.9%  
From Investments Rs m-1,432-18,404 7.8%  
From Financial Activity Rs m-1,591-3,692 43.1%  
Net Cashflow Rs m-259-1,144 22.6%  

Share Holding

Indian Promoters % 45.9 25.5 180.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 5.4 211.1%  
FIIs % 25.3 35.3 71.7%  
ADR/GDR % 0.0 18.5 -  
Free float % 17.4 15.3 113.7%  
Shareholders   36,892 75,885 48.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   AUROBINDO PHARMA  ORCHID PHARMA LTD  GSK PHARMA  J.B.CHEMICALS  MERCK LTD  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; PSU & Healthcare Stocks Top Losers(09:30 am)

Asian equities are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1.20% while the Hang Seng is up 0.61%. The Shanghai Composite is trading up by 0.45%.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Feb 20, 2018 11:53 AM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS